[go: up one dir, main page]

JO3685B1 - صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها - Google Patents

صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Info

Publication number
JO3685B1
JO3685B1 JOP/2013/0281A JOP20130281A JO3685B1 JO 3685 B1 JO3685 B1 JO 3685B1 JO P20130281 A JOP20130281 A JO P20130281A JO 3685 B1 JO3685 B1 JO 3685B1
Authority
JO
Jordan
Prior art keywords
nanodispersion formulations
aqueous solvent
aqueous
methods
formulations
Prior art date
Application number
JOP/2013/0281A
Other languages
English (en)
Inventor
Nabeta Kiichiro
Original Assignee
Teikoku Pharma Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teikoku Pharma Usa Inc filed Critical Teikoku Pharma Usa Inc
Application granted granted Critical
Publication of JO3685B1 publication Critical patent/JO3685B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

<strong>يتم تجهيز تركيبات التشتت النانوي من التاكسين غير مائي خالي من الإيثانولز حيث تشتمل تركيبات التشتت النانوي وفقا لتجسيدات الإختراع الحالي على التاكسين و الزيت و مخفض التوتر السطحي غير أيونية و مذيب غير مائي و مكون حمض عضوي، حيث يكون مكون الحمض العضوي قابل للذوبان في مذيب غير مائي و تعادل الكمية بالنسبة للوزن من مخفضات التوتر السطحي غير أيونية أو أكبر من الكمية بالنسبة لوزن مذيب غير مائي. و يتم تجهيز تركيبات التشتت النانوى من الدوسيتاكسيل غير مائي خالي من الإيثانول. حيث تشتمل تركيبات التشتت النانوى وفقا لتجسيدات الاختراع الحالي على الدوسيتاكسيل و زيت و مخفض التوتر السطحي أيونية و مذيب غير مائي و تكون خالية تماما من أي قاعدة مترافقة. و يتم تقديم طرق إستخدام تركيبات التشتت النانوى و كذلك عبوة لوازم التي تشتمل على هذه التركيبات.</strong>
JOP/2013/0281A 2012-10-01 2013-09-25 صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها JO3685B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261708595P 2012-10-01 2012-10-01
US201261708586P 2012-10-01 2012-10-01

Publications (1)

Publication Number Publication Date
JO3685B1 true JO3685B1 (ar) 2020-08-27

Family

ID=50385793

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0281A JO3685B1 (ar) 2012-10-01 2013-09-25 صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Country Status (21)

Country Link
US (4) US20140094510A1 (ar)
EP (1) EP2903435B1 (ar)
JP (1) JP2015534558A (ar)
KR (1) KR102165394B1 (ar)
CN (2) CN108464969B (ar)
AR (1) AR092759A1 (ar)
AU (1) AU2013327563B9 (ar)
BR (1) BR112015006692A2 (ar)
CA (1) CA2885930A1 (ar)
ES (1) ES2736054T3 (ar)
IL (1) IL237930B (ar)
IN (1) IN2015DN02661A (ar)
JO (1) JO3685B1 (ar)
MX (1) MX364948B (ar)
MY (1) MY173324A (ar)
PH (1) PH12015500681A1 (ar)
RU (1) RU2015116260A (ar)
SG (1) SG11201502352WA (ar)
TW (1) TWI624274B (ar)
WO (1) WO2014055426A1 (ar)
ZA (1) ZA201502686B (ar)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
CN110461311A (zh) 2016-08-26 2019-11-15 奥野哲治 微细纳米化药剂及其应用
KR20210078505A (ko) * 2018-10-16 2021-06-28 유에스 나노 푸드 앤 드럭 인코포레이티드 종양내 주사 제형
KR102557719B1 (ko) * 2019-04-26 2023-07-20 가톨릭대학교 산학협력단 항산화제가 담지된 나노입자를 유효성분으로 포함하는 귀 질환 치료용 약학 조성물
KR102401546B1 (ko) * 2020-03-25 2022-05-27 주식회사 보령 탁산, 이의 약학적으로 허용되는 염, 또는 그의 수화물을 함유하는 안정성이 향상된 신규 약제학적 제형
MX2022010387A (es) 2020-04-13 2022-09-05 US Nano Food & Drug INC Formulacion basica para inyeccion quimioterapeutica intratumoral.

Family Cites Families (218)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JPS6328743A (ja) 1986-07-23 1988-02-06 Oi Seisakusho Co Ltd 自動車用シ−トスライド装置
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5407683A (en) 1990-06-01 1995-04-18 Research Corporation Technologies, Inc. Pharmaceutical solutions and emulsions containing taxol
JPH04164024A (ja) 1990-10-29 1992-06-09 Sankyo Co Ltd 医薬物質含有自己乳化型脂肪乳剤組成物の製造方法
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
US5714512A (en) 1991-07-08 1998-02-03 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
US5750561A (en) 1991-07-08 1998-05-12 Rhone-Poulenc Rorer, S.A. Compositions containing taxane derivatives
FR2678833B1 (fr) 1991-07-08 1995-04-07 Rhone Poulenc Rorer Sa Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.
US5698582A (en) 1991-07-08 1997-12-16 Rhone-Poulenc Rorer S.A. Compositions containing taxane derivatives
DE4208527A1 (de) 1992-03-17 1993-09-23 Max Planck Gesellschaft Liposomen mit negativer ueberschussladung
FR2691460B1 (fr) 1992-05-21 1994-07-22 Rhone Poulenc Rorer Sa Nouveaux derives du taxane, leur preparation et les compositions qui les contiennent.
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
ATE169216T1 (de) 1992-11-27 1998-08-15 Napro Biotherapeutics Inc Paclitaxel enthaltende injizierbare zusammensetzung
FR2698543B1 (fr) 1992-12-02 1994-12-30 Rhone Poulenc Rorer Sa Nouvelles compositions à base de taxoides.
FR2698871B1 (fr) 1992-12-09 1995-02-24 Rhone Poulenc Rorer Sa Nouveau taxoïdes, leur préparation et les compositions pharmaceutiques qui les contiennent.
US5439686A (en) 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
DE69433723T3 (de) 1993-02-22 2008-10-30 Abraxis Bioscience, Inc., Los Angeles Verfahren für die in-vivo-verabreichung von biologischen substanzen und hierfür verwendbare zusammensetzungen
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
US20030133955A1 (en) 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US5785976A (en) 1993-03-05 1998-07-28 Pharmacia & Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
CA2091152C (en) 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
US5885486A (en) 1993-03-05 1999-03-23 Pharmaciaand Upjohn Ab Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof
FR2703049B1 (fr) 1993-03-22 1995-04-21 Rhone Poulenc Rorer Sa Procédé de purification des taxoïdes.
JP3526887B2 (ja) 1993-04-23 2004-05-17 帝國製薬株式会社 消炎鎮痛外用貼付剤
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
CA2180260A1 (en) 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
US5925669A (en) 1994-03-22 1999-07-20 Molecular/Structural Bio Technologies, Inc. Carrier compositions for anti-neoplastic drugs
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5616330A (en) 1994-07-19 1997-04-01 Hemagen/Pfc Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same
DE4430593C2 (de) 1994-08-20 1999-01-14 Max Delbrueck Centrum Verfahren zur Herstellung von Liposomal verkapseltem Taxol
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5789000A (en) 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US5580899A (en) 1995-01-09 1996-12-03 The Liposome Company, Inc. Hydrophobic taxane derivatives
US5716928A (en) 1995-06-07 1998-02-10 Avmax, Inc. Use of essential oils to increase bioavailability of oral pharmaceutical compounds
EP0760237A1 (en) 1995-08-30 1997-03-05 Cipla Limited Oil-in-water microemulsions
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6964946B1 (en) 1995-10-26 2005-11-15 Baker Norton Pharmaceuticals, Inc. Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
CA2240595A1 (en) * 1995-12-21 1997-07-03 Bijan Almassian Taxane composition and method
KR100330373B1 (ko) 1996-05-28 2002-11-07 주식회사한국신약 탁솔을 함유한 주사용 약제 조성물
US5877205A (en) 1996-06-28 1999-03-02 Board Of Regents, The University Of Texas System Parenteral paclitaxel in a stable non-toxic formulation
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US6727280B2 (en) 1997-01-07 2004-04-27 Sonus Pharmaceuticals, Inc. Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US6458373B1 (en) 1997-01-07 2002-10-01 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6121245A (en) 1997-01-29 2000-09-19 Firshein; Richard N. Method of treating cancer using alkylglycerols in conjunction with chemotherapy
US6334445B1 (en) 1997-03-27 2002-01-01 Baker Norton Pharmaceuticals, Inc. Methods and compositions for treatment of ovarian cancer
JP4865937B2 (ja) 1997-06-27 2012-02-01 アブラクシス バイオサイエンス、エルエルシー パクリタキセル製剤
CA2211949A1 (en) 1997-07-21 1999-01-29 David Farley Johnson Nonaqueous compositions for parenteral administration
AU728626B2 (en) 1997-07-29 2001-01-11 Pharmacia & Upjohn Company Pharmaceutical composition for acidic lipophilic compounds in a form of a self-emulsifying formulation
PL192080B1 (pl) 1997-07-29 2006-08-31 Upjohn Co Kompozycja farmaceutyczna zawierająca związek piranonowy
US6090407A (en) 1997-09-23 2000-07-18 Research Development Foundation Small particle liposome aerosols for delivery of anti-cancer drugs
US6281175B1 (en) 1997-09-23 2001-08-28 Scimed Life Systems, Inc. Medical emulsion for lubrication and delivery of drugs
AU743098B2 (en) 1997-12-10 2002-01-17 Cyclosporine Therapeutics Limited Pharmaceutical compositions containing an omega-3 fatty acid oil
EP1059941B1 (en) 1998-03-05 2004-05-26 Phares Pharmaceutical Research N.V. Pharmaceutical compositions and their use
IL131217A0 (en) 1998-03-10 2001-01-28 Napro Biotherapeutics Inc Novel methods and compositions for delivery of taxanes
US6979456B1 (en) 1998-04-01 2005-12-27 Jagotec Ag Anticancer compositions
WO1999049848A1 (en) * 1998-04-01 1999-10-07 Rtp Pharma Inc. Anticancer compositions
JP2002513750A (ja) 1998-05-07 2002-05-14 エラン コーポレーシヨン ピーエルシー 溶媒／助溶剤を含まないマイクロエマルジョン及びエマルジョンプレ濃縮物のドラッグデリバリーシステム
TR200003435T2 (tr) 1998-05-20 2001-03-21 The Liposome Company,Inc. Yeni parçacıklı formülasyonlar
US7030155B2 (en) 1998-06-05 2006-04-18 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
US6017948A (en) 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
US6071952A (en) 1998-12-02 2000-06-06 Mylan Pharmaceuticals, Inc. Stabilized injectable pharmaceutical compositions containing taxoid anti-neoplastic agents
US6638522B1 (en) 1998-12-11 2003-10-28 Pharmasolutions, Inc. Microemulsion concentrate composition of cyclosporin
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6761903B2 (en) 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US6537585B1 (en) 1999-03-26 2003-03-25 Guilford Pharmaceuticals, Inc. Methods and compositions for treating solid tumors
EP1171117A4 (en) 1999-04-22 2002-08-07 American Bioscience Inc LONG-TERM ADMINISTRATION OF PHARMACOLOGICALLY ACTIVE AGENTS
BR0010794A (pt) * 1999-05-24 2002-06-04 Sonus Pharma Inc Emulsão-veìculo para drogas com fraca solubilidade
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
EP1479382A1 (en) 1999-06-18 2004-11-24 IVAX Research, Inc. Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same
TW422706B (en) 1999-07-01 2001-02-21 Wang Iz Rung An oil-in-water emulsion type of paclitaxel
GB9920548D0 (en) 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
CA2383233C (en) 1999-09-21 2010-06-08 Rtp Pharma Inc. Surface modified particulate compositions of biologically active substances
US6348215B1 (en) 1999-10-06 2002-02-19 The Research Foundation Of State University Of New York Stabilization of taxane-containing dispersed systems
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
US6828346B2 (en) 1999-10-25 2004-12-07 Supergen, Inc. Methods for administration of paclitaxel
RU2002113659A (ru) 1999-10-27 2004-01-27 Бейкер Нортон Фармасьютикалз, Инк. (Us) Способ и композиции для перорального введения таксанов больным людям
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
US6638973B2 (en) 2000-02-02 2003-10-28 Fsu Research Foundation, Inc. Taxane formulations
AU2001247726A1 (en) 2000-03-24 2001-10-08 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
JP3448006B2 (ja) 2000-03-29 2003-09-16 独立行政法人食品総合研究所 機能性エマルション
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US6761901B1 (en) 2000-05-02 2004-07-13 Enzrel Inc. Liposome drug delivery
AU2001266272B2 (en) 2000-05-03 2005-09-15 Medigene Ag Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
DE10036871A1 (de) 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US20020141966A1 (en) 2000-11-16 2002-10-03 Wenbin Dang Compositions for treatment of malignant effusions, and methods of making and using the same
ES2289015T3 (es) 2000-11-29 2008-02-01 Lyotropic Therapeutics, Inc. Sistemas de disolventes para agentes farmaceuticos.
US20030099674A1 (en) 2001-08-11 2003-05-29 Chen Andrew X. Lyophilized injectable formulations containing paclitaxel or other taxoid drugs
AU2002357012A1 (en) 2001-11-27 2003-06-10 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
US6815642B2 (en) 2001-12-19 2004-11-09 Delphi Technologies, Inc. Apparatus and method for heating a steering wheel
BR0311530A (pt) 2002-05-23 2005-05-10 Umd Inc Compostos e método de liberação para droga transmucosal e para crio-proteção
DK1529044T5 (da) 2002-08-02 2008-04-21 Nereus Pharmaceuticals Inc Dehydrophenylahistiner og analoger deraf og syntesen af dehydrophenylahistiner og analoger deraf
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
CA2494825C (en) 2002-08-21 2009-02-17 Pharmacia Corporation Injectable pharmaceutical suspension in a two-chamber vial
US20080220074A1 (en) 2002-10-04 2008-09-11 Elan Corporation Plc Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same
AU2003268380A1 (en) 2002-10-04 2004-05-04 Elan Pharma International Limited Gamma irradiation of solid nanoparticulate active agents
JP2006514698A (ja) 2002-10-30 2006-05-11 スフェリックス， インコーポレイテッド ナノ粒子生物活性物質
EP1558241A2 (en) 2002-11-08 2005-08-03 Bristol-Myers Squibb Company Pharmaceutical compositions and methods of using taxane derivatives
US6838569B2 (en) 2002-12-16 2005-01-04 Dabur India Limited Process for preparation of paclitaxel trihydrate and docetaxel trihydrate
US20040219214A1 (en) 2002-12-30 2004-11-04 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US8703982B2 (en) 2003-03-17 2014-04-22 Phyton Holdings Llc Purification of taxanes
CA2527429A1 (en) 2003-05-30 2004-12-09 Arc Pharmaceuticals, Inc. Pharmaceutical compositions and methods relating to inhibiting fibrous adhesions using various agents
EP1498120A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Semi-solid formulations for the oral administration of taxoids
EP1498143A1 (en) 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
US20060292186A1 (en) 2003-08-29 2006-12-28 Novagali Pharma Sa Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
EP1694660B1 (en) 2003-12-12 2009-04-08 Quiral Quimica Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7345093B2 (en) 2004-04-27 2008-03-18 Formatech, Inc. Methods of enhancing solubility of compounds
US20060052951A1 (en) 2004-05-07 2006-03-09 Yaffe Michael B Methods and compositions for cancer treatment relating to BRCA1 BRCT domain recognition of phosphorylated BACH1
US8557861B2 (en) 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US7446126B2 (en) 2004-10-08 2008-11-04 Indena S.P.A. Semisynthesis process for the preparation of 10-deacetyl-N-debenzoyl-paclitaxel
US20080064760A1 (en) 2004-10-29 2008-03-13 Ping Li Spontaneously Dispersible Pharmaceutical Composition
JP4734910B2 (ja) 2004-12-09 2011-07-27 日油株式会社 難水溶性薬剤用可溶化剤組成物
EP1855659A2 (en) 2005-02-24 2007-11-21 Elan Pharma International Limited Nanoparticulate formulations of docetaxel and analogues thereof
ITMI20050614A1 (it) 2005-04-12 2006-10-13 Indena Spa Processo per la purificazione della 10-deacetilbaccatina iii dalla 10-deacetil-2-debenzoil-2-pentenoilbaccatina iii
WO2006133510A1 (en) 2005-06-17 2006-12-21 Hospira Australia Pty Ltd Liquid pharmaceutical formulations of docetaxel
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
WO2007027941A2 (en) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
RU2433818C2 (ru) 2005-08-31 2011-11-20 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
US20070142457A1 (en) 2005-10-12 2007-06-21 Alessandro Pontiroli Crystalline forms of docetaxel and processes for their preparation
EA015781B1 (ru) 2005-10-21 2011-12-30 Панацея Биотек Лимитед Композиции для лечения рака
AR057909A1 (es) 2005-11-18 2007-12-26 Synthon Bv Proceso para preparar montelukast y compuestos relacionados, que utiliza un compuesto intermediario derivado de un ester sulfonico.
CZ300305B6 (cs) 2005-12-20 2009-04-15 Heaton, A. S. Farmaceutická kompozice obsahující derivát taxanu se zlepšenou terapeutickou úcinností
JP2009521463A (ja) 2005-12-21 2009-06-04 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体のための方法およびそれに有用な中間体
EP1973892A1 (en) 2005-12-21 2008-10-01 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
KR100995390B1 (ko) 2006-01-02 2010-11-19 주식회사 삼양제넥스 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법
EP1808173A1 (en) 2006-01-12 2007-07-18 Matthias Dormeyer Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
BRPI0600285C1 (pt) 2006-01-13 2011-10-11 Brz Biotecnologia Ltda compostos farmacêuticos contendo nanopartìculas úteis para tratamento de lesões reestenóticas
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
WO2007083316A2 (en) 2006-01-23 2007-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug
BRPI0600194A (pt) * 2006-01-30 2007-10-23 Quiral Quimica Do Brasil S A composições farmacêuticas contendo docetaxel e um inibidor de degradação e processo de obtenção das mesmas
CN101023940A (zh) 2006-02-20 2007-08-29 郝守祝 一种紫杉烷类化合物的药用组合物、制备方法及用途
WO2007096900A1 (en) 2006-02-21 2007-08-30 Dabur Pharma Limited Stable pharmaceutical composition of taxanes
CA2645080A1 (en) 2006-03-07 2007-09-13 Novavax,Inc. Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
AU2007226937A1 (en) 2006-03-21 2007-09-27 Dr. Reddy's Laboratories Ltd. Docetaxel polymorphs and processes
AU2007245085A1 (en) 2006-03-27 2007-11-08 Tapestry Pharmaceuticals, Inc. A convergent process for the synthesis of taxane derivatives
JP2009532489A (ja) 2006-04-03 2009-09-10 テバ ファーマシューティカル インダストリーズ リミティド 薬剤微粒子
AU2007246077A1 (en) 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
KR100917809B1 (ko) 2006-05-22 2009-09-18 에스케이케미칼주식회사 우수한 저장안정성을 갖는 도세탁셀 함유 주사제 조성물
CN1857222B (zh) 2006-06-05 2010-05-12 中国医药研究开发中心有限公司 多西紫杉醇静脉注射亚微乳剂及其制备方法
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
US20100034749A1 (en) 2006-07-10 2010-02-11 Medigene Ag Use of a Cationic Collodal Preparation for the Diagnosis and Treatment of Ocular Diseases
WO2008013785A2 (en) 2006-07-24 2008-01-31 Singh-Broemer And Company, Inc. Solid nanoparticle formulation of water insoluble pharmaceutical substances with reduced ostwald ripening
WO2008026048A2 (en) 2006-08-31 2008-03-06 Wockhardt Research Centre Stable injectable pharmaceutical compositions of docetaxel
NZ576355A (en) 2006-10-20 2012-04-27 Scinopharm Singapore Pte Ltd Process for making crystalline anhydrous docetaxel
EP2086508A2 (en) 2006-11-03 2009-08-12 MediGene Aktiengesellschaft Cationic colloidal carriers for delivery of active agents to the blood-brain barrier in the course of neuroinflammatory diseases
CN100998560A (zh) 2006-12-27 2007-07-18 沈阳药科大学 多烯紫杉醇冻干乳剂及其制备方法
EP1946747A1 (en) 2007-01-17 2008-07-23 Sandoz AG Pharmaceutical composition of improved stability containing taxane derivatives
CN101244053B (zh) * 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 以多西他赛为主组分的新的分散体系
WO2008102374A1 (en) 2007-02-20 2008-08-28 Dabur Pharma Limited Amorphous form of docetaxel
AU2008227852B2 (en) 2007-03-19 2011-02-24 Fresenius Kabi Oncology Ltd. Proliposomal and liposomal compositions
KR100878455B1 (ko) 2007-04-10 2009-01-13 한미약품 주식회사 안정한 무수결정형 도세탁셀 및 이의 제조방법
EP2146695A4 (en) 2007-04-23 2010-05-19 Sun Pharmaceuticals Ind Ltd PHARMACEUTICAL COMPOSITIONS
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
EP2170319A4 (en) 2007-06-22 2011-10-12 Scidose Llc SOLVENT FORMULATION FROM DOCETAXEL WITHOUT TWEEN 80
EP2173732A4 (en) 2007-07-04 2011-09-07 Reddys Lab Ltd Dr PROCESSES FOR THE PREPARATION OF DOCETAXEL AND POLYMORPHIC
CN101396354B (zh) 2007-09-30 2010-12-01 江苏恒瑞医药股份有限公司 一种稳定的塔三烷类化合物液体组合物及其制备方法和其应用
EP2205215A2 (en) 2007-10-01 2010-07-14 Intas Pharmaceuticals Limited Docetaxel injectable composition, being absolutely free of ethanol
FR2922107B1 (fr) 2007-10-10 2010-02-26 Aventis Pharma Sa Nouvelles compositions a base de taxoides
EP2205580A1 (en) 2007-10-23 2010-07-14 Antisoma Research Limited Crystalline forms of dmxaa sodium salt
US20090130198A1 (en) 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8586062B2 (en) 2007-12-24 2013-11-19 Sun Pharma Advanced Research Company Ltd. Nanodispersion
KR101053780B1 (ko) * 2008-02-29 2011-08-02 동아제약주식회사 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
CN101525321B (zh) 2008-03-06 2012-03-07 上海希迪制药有限公司 多烯紫杉醇倍半水结晶体及其制备方法
EP2265618A2 (en) 2008-03-14 2010-12-29 Sunesis Pharmaceuticals, Inc. Aurora kinase inhibitors
US20110206739A1 (en) 2008-03-28 2011-08-25 University Of Massachusetts Compositions and methods for the preparation of nanoemulsions
JP2011516472A (ja) 2008-04-04 2011-05-26 ショール，ロバート 微小管相互作用薬の脂質−油−水型ナノエマルジョンデリバリシステム
TR201905480T4 (tr) 2008-04-18 2019-05-21 Angiochem Inc Paklitaksel, paklitaksel analogları veya paklitaksel konjugatlarının farmasötik bileşimleri ve ilgili preparasyon ve kullanım yöntemleri.
MX2011000795A (es) * 2008-07-23 2011-03-29 Bharat Serums & Vaccines Ltd Nanoemulsion estable inyectable de docetaxel de aceite en agua.
KR20100018741A (ko) * 2008-08-07 2010-02-18 신풍제약주식회사 도세탁셀 함유 항암용 주사제 조성물
ES2344674B1 (es) 2008-08-07 2011-06-29 Gp Pharm, S.A. Composicion farmaceutica inyectable de taxanos.
CN101366697A (zh) * 2008-08-14 2009-02-18 沈阳万爱普利德医药科技有限公司 一种新的包含紫杉醇类物质的注射用纳米脂质载体及其制备方法
WO2010023321A1 (en) 2008-09-01 2010-03-04 Stragen Pharma S.A. Liquid formulation containing a taxane derivative
WO2010033771A2 (en) 2008-09-19 2010-03-25 Trustees Of The University Of Pennsylvania Modulators of hsp70/dnak function and methods of use thereof
EP2172193A1 (en) 2008-10-02 2010-04-07 Capsulution Nanoscience AG Improved nanoparticulate compositions of poorly soluble compounds
WO2010045292A2 (en) * 2008-10-15 2010-04-22 The University Of North Carolina At Chapel Hill Nanoparticle compositions comprising liquid oil cores
US9060926B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8849441B2 (en) 2008-10-31 2014-09-30 The Invention Science Fund I, Llc Systems, devices, and methods for making or administering frozen particles
US9072688B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8409376B2 (en) 2008-10-31 2013-04-02 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US8731841B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US9050251B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US9060931B2 (en) 2008-10-31 2015-06-23 The Invention Science Fund I, Llc Compositions and methods for delivery of frozen particle adhesives
US8731840B2 (en) 2008-10-31 2014-05-20 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US20100111831A1 (en) 2008-10-31 2010-05-06 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Compositions and methods for surface abrasion with frozen particles
US8784385B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Frozen piercing implements and methods for piercing a substrate
US8762067B2 (en) 2008-10-31 2014-06-24 The Invention Science Fund I, Llc Methods and systems for ablation or abrasion with frozen particles and comparing tissue surface ablation or abrasion data to clinical outcome data
US8788211B2 (en) 2008-10-31 2014-07-22 The Invention Science Fund I, Llc Method and system for comparing tissue ablation or abrasion data to data related to administration of a frozen particle composition
US9072799B2 (en) 2008-10-31 2015-07-07 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US9050317B2 (en) 2008-10-31 2015-06-09 The Invention Science Fund I, Llc Compositions and methods for therapeutic delivery with frozen particles
US8603495B2 (en) 2008-10-31 2013-12-10 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8725420B2 (en) 2008-10-31 2014-05-13 The Invention Science Fund I, Llc Compositions and methods for surface abrasion with frozen particles
US20100111841A1 (en) 2008-10-31 2010-05-06 Searete Llc Compositions and methods for surface abrasion with frozen particles
US8551506B2 (en) 2008-10-31 2013-10-08 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
US8545806B2 (en) 2008-10-31 2013-10-01 The Invention Science Fund I, Llc Compositions and methods for biological remodeling with frozen particle compositions
US8563012B2 (en) 2008-10-31 2013-10-22 The Invention Science Fund I, Llc Compositions and methods for administering compartmentalized frozen particles
WO2010059916A2 (en) 2008-11-20 2010-05-27 Dr. Reddy's Laboratories Ltd. Preparation of docetaxel
KR101093720B1 (ko) * 2009-03-06 2011-12-19 지웅길 주사제용 항암제 조성물
WO2010128504A2 (en) 2009-05-04 2010-11-11 Ben-Gurion University Of The Negev Research And Development Authority Nano-sized particles comprising multi-headed amphiphiles for targeted drug delivery
JP5497336B2 (ja) 2009-05-20 2014-05-21 テクノガード株式会社 薬物を保持した脂肪粒子を含む非水系組成物およびその製造方法
KR101074936B1 (ko) * 2009-05-25 2011-10-18 보령제약 주식회사 도세탁셀 주사제용 조성물 및 그의 제조방법
PL388144A1 (pl) 2009-05-29 2010-12-06 Przedsiębiorstwo Produkcyjno-Wdrożeniowe Ifotam Spółka Z Ograniczoną Odpowiedzialnością Solwaty (2R,3S)-3-tert-butoksykarbonylamino-2-hydroksy-3-fenylopropionianu 4-acetoksy-2α-benzoiloksy -5β,20-epoksy-1,7β,10β-trihydroksy-9-okso-taks-11-en-13α-ylu, sposób ich otrzymywania i zastosowanie
EP2442805A4 (en) 2009-06-19 2012-11-21 Sun Pharma Advanced Res Co Ltd NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME
EP2470019A4 (en) * 2009-08-25 2013-03-13 Cardiokine Biopharma Llc COMPOSITIONS FOR THE ADMINISTRATION OF NON-SOLUBLE AGENTS
CN102038635A (zh) 2009-10-23 2011-05-04 天津天士力集团有限公司 一种含有pH值调节剂的紫杉烷类药物溶液及其制备方法
ES2621613T3 (es) 2009-11-04 2017-07-04 Emcure Pharmaceuticals Limited Un proceso mejorado para la preparación de derivados de taxano
KR101149600B1 (ko) 2009-12-31 2012-05-29 주식회사 삼양제넥스바이오 고순도 무수결정형 도세탁셀 제조방법
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
SG10201503234SA (en) 2010-05-03 2015-06-29 Teikoku Pharma Usa Inc Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
WO2012160568A1 (en) 2011-05-23 2012-11-29 Shilpa Medicare Limited Process for preparing docetaxel trihydrate polymorph
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها

Also Published As

Publication number Publication date
MX364948B (es) 2019-05-15
KR20150066542A (ko) 2015-06-16
WO2014055426A1 (en) 2014-04-10
US20160206560A1 (en) 2016-07-21
IL237930B (en) 2019-06-30
CN108464969B (zh) 2022-03-25
IN2015DN02661A (ar) 2015-09-04
HK1259184A1 (zh) 2019-11-29
TWI624274B (zh) 2018-05-21
ZA201502686B (en) 2016-02-24
AU2013327563B2 (en) 2017-05-11
EP2903435A1 (en) 2015-08-12
US20140094509A1 (en) 2014-04-03
RU2015116260A (ru) 2016-11-27
JP2015534558A (ja) 2015-12-03
AU2013327563B9 (en) 2017-05-25
US20150094361A1 (en) 2015-04-02
EP2903435B1 (en) 2019-06-12
SG11201502352WA (en) 2015-04-29
AR092759A1 (es) 2015-04-29
CN108464969A (zh) 2018-08-31
PH12015500681A1 (en) 2015-05-18
MY173324A (en) 2020-01-15
CA2885930A1 (en) 2014-04-10
IL237930A0 (en) 2015-05-31
ES2736054T3 (es) 2019-12-23
MX2015003824A (es) 2015-11-06
US9308195B2 (en) 2016-04-12
EP2903435A4 (en) 2016-05-25
AU2013327563A1 (en) 2015-04-16
BR112015006692A2 (pt) 2017-08-08
CN104822262A (zh) 2015-08-05
US20140094510A1 (en) 2014-04-03
CN104822262B (zh) 2018-05-22
TW201417842A (zh) 2014-05-16
KR102165394B1 (ko) 2020-10-15
US8940786B2 (en) 2015-01-27
HK1210665A1 (en) 2016-05-06
US9763880B2 (en) 2017-09-19

Similar Documents

Publication Publication Date Title
WO2014086982A3 (en) Stable metal compounds, their compositions and methods of their use
IN2014DN09346A (ar)
PH12015500681A1 (en) Non-aqueous taxane nanodispersion formulations and methods of using the same
IN2015DN00960A (ar)
MX2015005944A (es) Cepas microbianas, composiciones y metodos para incrementar el fosfato disponible para las plantas.
WO2013177419A3 (en) Lipid nanoparticle compositions and methods of making and methods of using the same
IN2015DN01315A (ar)
EA201590887A1 (ru) Композиция
MA37601A1 (fr) Formulations pharmaceutiques topiques non aqueuses et non desquamantes pour utilsation comme antiacterien
WO2011140341A3 (en) Cosmetic compositions containing acrylic thickener
PH12016500643A1 (en) New octahydro - cyclobuta [1,2-c;3,4-c`] dipyrrol -2- yl
HK1217489A1 (zh) Flap调节剂
EA201491195A1 (ru) Способ получения композиции, содержащей галактоолигосахариды
MY167224A (en) Non-Aqueous Taxane Pro-Emulsion Formulations and Methods of Making and Using the Same
UA112132C2 (uk) Обробка розчинної кави
CA2872376A1 (en) 6-pyridone-2-carbamoyl-azoles and their use as herbicides
TN2015000008A1 (en) Method for preparing substituted triazolopyridines
MX359955B (es) Formulación de aroma y fragancia (iii).
EA201590846A1 (ru) Клизмы
IN2012DN05888A (ar)
MD4258B1 (en) The use of biologically active coordinative compounds of copper(II) with 4-(methoxyphenyl)thiosemicarbazones of 2-benzoylpyridine as inhibitors of Candida albicans
WO2012004073A3 (de) Verwendung von beta-isophoron als lösemittel
UA73351U (en) rail steel
WO2011140351A3 (en) Anhydrous compositions containing acrylic thickener
UA74739U (ru) Олигоуретанаммония хлорид в качестве поверхностно-активного вещества